Abstract. High hydrostatic pressure (HHP) has been shown to induce immunogenic cell death of cancer cells, facilitating their uptake by dendritic cells (DC) and subsequent presentation of tumor antigens. In the present study, we demonstrated immunogenicity of the HHP-treated tumor cells in mice. HHP was able to induce immunogenic cell death of both TC-1 and TRAMP-C2 tumor cells, representing murine models for human papilloma virus-associated tumors and prostate cancer, respectively. HHP-treated cells induced stronger immune responses in mice immunized with these tumor cells, documented by higher spleen cell cytotoxicity and increased IFNγ production as compared to irradiated tumor cells, accompanied by suppression of tumor growth in vivo in the case of TC-1 tumors, but not TRAMP-C2 tumors. Furthermore, HHP-treated cells were used for DC-based vaccine antigen pulsing. DC co-cultured with HHP-treated tumor cells and matured by a TLR 9 agonist exhibited higher cell surface expression of maturation markers and production of IL-12 and other cytokines, as compared to the DC pulsed with irradiated tumor cells. Immunization with DC cellbased vaccines pulsed with HHP-treated tumor cells induced high immune responses, detected by increased spleen cell cytotoxicity and elevated IFNγ production. The DC-based vaccine pulsed with HHP-treated tumor cells combined with docetaxel chemotherapy significantly inhibited growth of both TC-1 and TRAMP-C2 tumors. Our results indicate that DC-based vaccines pulsed with HHP-inactivated tumor cells can be a suitable tool for chemoimmunotherapy, particularly with regard to the findings that poorly immunogenic TRAMP-C2 tumors were susceptible to this treatment modality.
Introduction
Cancer immunotherapy, especially when combined with other therapeutic modalities such as chemotherapy, is an attractive approach to cancer treatment. Synergistic effects of combinations of immunotherapy and chemotherapy have been demonstrated in a number of pre-clinical and clinical studies (1, 2) .
Dendritic cells (DCs) are key players in the immune response as they are able to capture antigens with their pattern-recognition receptors, to process and present them to naïve T-cells, inducing their activation (3) , and thus building an essential bridge between innate and adaptive responses. The possibility of their generation in vitro enabled their use for immunotherapy of cancer (4) , and a number of clinical trials have been performed in the last decade (5, 6) . Typically, an autologous dendritic cell-based vaccine represents in vitro cultured dendritic cells pulsed with tumor antigens that can be in the form of tumor cells with subsequent DC maturation. For DC pulsing, tumor cells can be inactivated by their lysis (ultrasonic treatment, repeated freeze-thaw), lethal irradiation or other methods before mixing them with DC. Selection of the optimal inactivation method can be crucial for DC vaccine optimization, together with selection of proper maturationinducing agents.
Therefore, a significant effort has also been invested in increasing the immunogenicity of dying cancer cells used
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2
tumors when combined with docetaxel chemotherapy for vaccine production. Until now several chemotherapeutic agents [anthracyclines (7) , oxaliplatin, platinum complexes (8) , bortezomib (9) ] and physical modalities [Uv-C, irradiation (10) , HHp] have been identified as inducers of immunogenic cell death (ICD). ICD is characterized by the cell-surface expression and release of damage associated molecular patterns (DAMPs). DAMPs found to be crucial for ICD include surface exposed chaperone protein calreticulin (CRT) and heat shock proteins 70 (HSP70) and 90 (HSP90), actively secreted ATP and passively released high-mobility group box 1 protein (HMGB1). These signals can activate innate immunity and, importantly, interact with phagocytosis-related receptors, purinergic receptors and pattern-recognition receptors expressed by DCs and thereby stimulate presentation of tumor antigens to T cells. High hydrostatic pressure (HHP) has been demonstrated as a convenient tool for tumor cell inactivation preserving their immunogenic capacity (11, 12) . Recently, induction of ICD by HHP has been shown in several human tumor cell lines. HHP-treated cells were able to induce monocyte-derived DC maturation, and DC co-cultured with HHP-treated tumor cells were able to induce T cell activation in vitro. These encouraging results suggest that HHP can be an important tool for tumor cell inactivation before their use for DC pulsing or as cellular vaccines (13) .
Chemotherapeutic drugs affect rapidly growing cells and, as a consequence, cause collateral damage to cells of the immune system. In this regard, they are considered immunosuppressive. However, there is increasing evidence that some cancer chemotherapies may actually aid the immunotherapy by activating the immune system rather than suppressing it (14, 15) . Chemotherapeutic drugs such as cyclophosphamide, doxorubicin, paclitaxel or docetaxel (16) were reported to possess immunomodulatory activities and appeared to be suitable for chemoimmunotherapy (17, 18) . Docetaxel is a widely used chemotherapeutic drug and represents a first-line chemotherapy for metastatic castrationresistant prostate cancer (19, 20) . The autologous dendritic cell-based vaccines are intensively studied as an immunotherapy for prostate cancer, and the first cellular immunotherapy based on activated peripheral blood mononuclear cells, Sipuleucel T, has been FDA-approved (21) . Collectively, combination chemoimmunotherapy based on docetaxel combined with the DC treatment represents an attractive modality for advanced prostate cancer therapy.
In the present study, we investigated, using murine tumor models, the immunogenicity of the HHP-inactivated tumor cells in vivo and, furthermore, the possibility to use HHP-treated tumor cells for preparation of DC-based vaccines. we have demonstrated the therapeutic capacity of the HHP cells-pulsed DC vaccines in combination with docetaxel treatments to inhibit growth of the TRAMP-C2 and TC-1 murine tumors. we have focused on the immunotherapy of poorly immunogenic TRAMP-C2 tumors, an animal model of prostate cancer treatment. For comparison, the study was completed with experiments using immunogenic TC-1 tumors representing a murine model for human papilloma virus 16-associated tumors, previously shown to be sensitive to the experimental DC treatments in various settings (22) (23) (24) .
Materials and methods
Mice. C57BL/6 male mice, 6-8 weeks old, were obtained from AnLab Ltd., Prague, Czech Republic. Experimental protocols were approved by the Institutional Animal Care Committee of the Institute of Molecular Genetics, Prague.
Tumor cell lines. The TC-1 tumor cell line (obtained from the ATCC collection) was developed by co-transfection of murine C57BL/6 lung cells with HPv16 E6/E7 genes and activated (G12v) Ha-ras plasmid DNA (25) . TRAMP-C2 tumor cells (obtained from the aTCC collection), MHC class I-deficient, were established from a heterogeneous 32-week tumor of the transgenic adenocarcinoma mouse prostate (TRAMP) model (26) . TC-1 cells were maintained in RPMI-1640 medium (Sigma-Aldrich GmbH, Steinheim, Germany) supplemented with 10% FCS (PAN Biotech GmbH, Aidenbach, Germany), 2 mM L-glutamine and antibiotics; TRAMP-C2 cells were maintained in D-MEM medium (Sigma-Aldrich) supplemented with 5% FCS, Nu-Serum Iv (5%; BD Biosciences, Bedford, MA, USA), 0.005 mg/ml human insulin (Sigma-Aldrich), dehydroisoandrosterone (DHEA, 10 nM; Sigma-Aldrich) and antibiotics. Both cell lines were cultured at 37˚C in a humidified atmosphere with 5% Co 2 cells. In the in vivo experiments, 5x10 4 TC-1 cells and 1x10 6 TRAMP-C2 cells were administered for the challenge. In our hands, 5x10 4 TC-1 cells represent 5 TID 50 doses and 1x10 6 TRAMP-C2 cells represent 3 TID 50 doses.
High hydrostatic pressure and irradiation cell treatments.
Tumor cells were treated by HHP (100, 150, 175 and 200 MPa) in the custom-made device (Resato International Bv, Roden, the Netherlands) that is located in the GMP manufacturing facility, Sotio a.s. (Prague, Czech Republic). This device allows reliable treatment of the tumor cells by defined levels of HHp for specified periods of time (10 min in the case of 200 MPa) (13) . Inactivation of tumor cells by irradiation (150 Gy) was performed as previously described (22) .
Dendritic cell preparation. Dendritic cells (DC) were prepared from bone marrow precursors as described by Indrová et al (24) and Lutz et al (27) with slight modifications (28) . Briefly, the bone marrow cells were cultured for 7 days in the complete RPMI-1640 medium supplemented with 2x10 -5 M mercaptoethanol (Calbiochem, La Jolla, CA, USA), 10 ng/ml GM-CSF and IL-4 (R&D Systems, Minneapolis, MN, USA). On day 5, the DC were pulsed with HHP-treated or irradiated (IR-treated) tumor cells by 48-h incubation in the ratio of 2:1 (DC/tumor cells, 10 6 DC/ml). DC pulsed with the tumor cells were treated for 24 h with unmethylated CpG containing phosphorothioate-modified oligodeoxynucleotide CpG 1826 (5'-TCCATGACGTTCCTGACGTT-3') (29) at a final concentration of 5 µg/ml (Generi Biotech, Hradec králové, Czech republic), were sulfur-modified in their backbone (phosphorothioate) and synthesized under endotoxin-free conditions. On day 7, non-adherent cells were harvested. These cells, designated as DC, contained ~60-70% CD11c ). For in vitro analyses of the immune response, three mice were sacrificed. Single-cell suspensions from the spleens were prepared by homogenization through a cell strainer (70 µm; BD Biosciences, San Jose, CA, USA). Erythrocytes were osmotically lysed using ammonium chloride-potassium lysis buffer, the cell suspension was washed three times in the RPMI-1640 medium and used for further analysis by FACS, chromium release assay, ELISA (IFNγ) and ELISPOT (IFNγ). Flow cytometry. Cell surface expression of CRT, HSP90, MHC class I, CD54 and CD80 on the tumor cells was analyzed by flow cytometry. Tumor cells were collected from the cell culture 24 h after the HHP or IR treatment [10 6 cells/ml/well, 12-well plate (Nunc, Roskilde, Denmark)]. Cells (5x10 5 /sample) were washed and labeled with primary antibodies for 25 min at 4˚C, followed by wash steps and alternatively labeled by incubation with Alexa 647-or DyLight 649-conjugated secondary antibody for 30 min at 4˚C. apoptotic cells were determined by annexin v apoptosis detection kit (eBiosciences) according to the manufacturer's instructions. Samples were kept in the dark and 10 min before the analysis, Hoechst 33258 was added at a final concentration of 2 µg/ml. Expression of cell surface molecules on the DC or spleen cells was analyzed by flow cytometry. Cell suspensions were washed and preincubated with anti-CD16/CD32 antibody to minimize non-specific binding for 15 min at 4˚C following washing step and incubation with labeled primary antibody for 30 min at 4˚C. relevant isotype controls of irrelevant specificity were used. FaCS buffer (pBS, 1% FBS, 0.1% nan 3 Confocal microscopy. HHP-treated TC-1 and TRAMP-C2 cells were collected and washed twice with PBS. The cells were then incubated for 30 min with primary anti-CRT antibody (FMC 75; Enzo Life Sciences) diluted in PBS, followed by washing and incubation with the Alexa Fluor 488 goat antimouse secondary antibody (Molecular Probes). Cells were washed twice with pBS and fixed in 4% paraformaldehyde for 20 min and mounted on slides. Cells were examined under a DMI 6000 inverted Leica TCS AOBS SP5 tandem scanning confocal microscope with an AR (488 nm) laser and an x63 oil immersion objective.
ELISA. For HMGB1 release, supernatants from the tumor cell culture were collected 24 h after HHP treatment (10 6 cell/ml/well, 12-well plate (Nunc) and analyzed by an ELISA kit (IBL International GmbH, Hamburg, Germany) according to the manufacturer's instructions. For IL-1β, IL-6, IFNγ and IL-12 production, supernatants from the DC culture were collected 24 h after the addition of CpG 1826 and analyzed by ELISA kits (BD Biosciences) according to the manufacturer's instructions. For IFNγ production, supernatants from the spleen single-cell suspension were collected after 48-h incubation [2x10 6 cell/ml/well, 12-well plate (Nunc)] and analyzed by an ELISA kit (BD Biosciences) according to the manufacturer's instructions.
ELISPOT. To determine the amount of IFNγ-secreting cells, an ELISPOT kit for detection of murine IFNγ (BD Biosciences, San Diego, CA, USA) was used. Spleen cells were cultured for 48 h and then placed into the wells of ELISPOT plates (concentration 5x10 5 , 1x10 5 and 5x10 4 cells/well) for 24 h. The plates were then processed according to the manufacturer's instructions (BD Biosciences). Colored spots were counted with CTL Analyzer LLC (CTL, Cleveland, OH, USA) and analyzed using ImmunoSpot Image Analyzer software.
Chromium release microcytotoxicity assay. The cytolytic activity of effector cells was tested in 18-h 51 Cr release assay, as previously described (32, 33) . Briefly, spleen cells from control and immunized mice that served as effector cells were treated with ammonium chloride-potassium lysing buffer (1 min) to deplete erythrocytes. The mixtures of effector cells with 
Results

HHP, but not IR, induces ICD markers on both TC-1 and TRAMP-C2 tumor cells.
First, we determined the ability of HHP to induce ICD in murine TC-1 or TRAMP-C2 cells, and then we compared the effect of HHP to the effect of irradiation (150 Gy) that has been standardly used for treatment of cells during preparation of DC vaccines in our previous studies (22) . Fig. 2B and C) . Fluorescence microscopy images of HHP-treated tumor cells stained for CrT confirmed increased expression of CrT after HHp treatment (Fig. 1D) . Release of HMGB1, late-stage ICD marker, in the supernatant was further analyzed. TRAMP-C2. Three mice from each group were left without challenge and used for parallel in vitro analyses. In vitro analyses of the spleen effector cells prepared ten days after the second immunization with HHP-treated TC-1 or TRAMP-C2 tumor cells showed an increased cytotoxic effect of spleen effector cells on the corresponding targets. In the group of mice immunized with IR-treated tumor cells, a similar but slightly lower effect was observed ( Fig. 2A and D) . Despite the fact that the analysis of the spleen effector cells after immunization with HHP-treated tumor cells showed only moderately augmented cytotoxic effect when compared to immunization with IR-treated tumor cells, analysis of IFNγ production revealed significant differences. Compared to the Ir-treated tumor cells, mice immunized with HHP-treated tumor cells displayed significantly increased IFnγ production by spleen cells measured by the eLISa assay ( Fig. 2B and e) and significantly increased number of IFNγ-producing cells detected by the ELISPOT assay ( Fig. 2C and F) . These results were similar in both tumor models, immunogenic TC-1 and weakly immunogenic TRAMP-C2. However, after the challenge of immunized mice with the corresponding tumor cells, significant inhibition (P<0.05) of tumor growth was recorded only in the groups of mice immunized with the HHP or IR-treated TC-1 tumor cells and challenged with corresponding TC-1 cells (Fig. 3B) . In contrast, mice immunized with HHP and IR-treated TRAMP-C2 cells did not exhibit any inhibition of tumor growth after the challenge with TRAMP-C2 cells (Fig. 3C) .
Pulsing with HHP-treated TC-1 or TRAMP-C2 tumor cells increased expression of maturation markers on DC
and stimulated production of cytokines characteristic for matured DC. Next, the HHP-treated TC-1 and TRAMP-C2 cells were used for DC pulsing, and the phenotypes of matured DC vaccines, unpulsed or pulsed with the IR-treated tumor cells or HHP-treated tumor cells, were compared (Fig. 4) . We did not see any significant differences between unpulsed cells and HHP-treated tumor cells-pulsed DC. In both cases, CpG ODN1826-mediated maturation increased Fig. 4A and B) . The ratio between the CD80 and CD274 cell surface expressions (demonstrated by MFI values) was higher on matured cells compared to the immature controls (Fig. 4A) . Both unpulsed cells and HHP-treated tumor cells-pulsed matured DC produced IL-12, as well as IL-1β, IL-6 and IFNγ (Fig. 4C) . HHP-treated tumor cellpulsed matured DC produced significantly higher amounts of IL-12 and IFNγ as compared to the unpulsed cells. No significant differences were observed between TraMp-C2 and TC-1 cell co-culture. On the other hand, pulsing with the IR-treated tumor cells resulted in reduction of the proportion of matured MHC class II high /CD86 high dendritic cells in the DC populations, decreased the ratio between the CD80 and CD274 cell surface expression, and also significantly inhibited IL-12, IFNγ and IL-1β production, as compared to both unpulsed cells and HHP-treated tumor cell-pulsed matured DC (Fig. 4) . These results indicate that DC co-culture with IR-treated, but not HHP-treated tumor cells, can impair DC maturation.
Prophylactic immunization with DC-based vaccine pulsed with HHP-treated TC-1 or TRAMP-C2 tumor cells induces strong immune response, but inhibits growth of TC-1 tumors only.
In the next series of experiments, HHP-treated tumor cell-pulsed matured DC were investigated in vivo. HHP-treated tumor cell-pulsed matured DC were selected for further in vivo experiments as pulsing of DC with IR-treated tumor cells negatively affected DC maturation in terms of expression of costimulatory molecules and production of selected cytokines. Mice were immunized twice in a 2-week interval with 2x10 6 HHP-treated tumor cell-pulsed matured DC. Ten days after the second immunization, mice were challenged with relevant tumor cells, in doses of 5x10 4 TC-1 or 10 6 TRAMP-C2 tumor cells. Three mice from each group were left without challenge and used for parallel in vitro analyses. Both HHP-treated TRAMP-C2 and TC-1 cells pulsed DC vaccines induced strong immune responses, as determined by spleen cell analysis performed ten days after the second immunization (Fig. 5) . Immunization with HHP-treated TC-1 or TraMp-C2 pulsed DC vaccines showed a significantly increased cytotoxic effect of spleen effector cells on the corresponding targets (Fig. 5A ). As compared with control mice, mice immunized with both HHP-treated TRAMP-C2 and TC-1 cells pulsed DC vaccines displayed significantly increased numbers of IFNγ-producing cells detected by eLISpoT assay (Fig. 5B) and significantly increased IFnγ production by spleen cells measured by ELISA assay (Fig. 5C ). a significant increase was also found in the percentage of CD4 + and CD8 + CD44 + CD62L -T lymphocytes ( Fig. 5D and  E) . These results were similar in both tumor models, immunogenic TC-1 and weakly immunogenic TRAMP-C2. Contrary to the results in vitro, in vivo analysis showed significant inhibition (P<0.05) of the tumor growth only in the group of mice immunized with the HHP-treated TC-1 tumor cell-pulsed matured DC and challenged with corresponding TC-1 cells (Fig. 6B ). Mice immunized with the HHP-treated TRAMP-C2 tumor cell-pulsed matured DC did not exhibit any inhibition of tumor growth after the challenge with TRAMP-C2 cells (Fig. 6C) . In both experiments, the percentage of tumor-free mice are shown in the right panel. control). Docetaxel alone delayed the growth of tumors, but no significant difference was evident. a representative experiment of two independent ones is given in Fig. 7B . when the incidences of tumors in mice from two performed experiments were merged [Control 19/19, docetaxel 18/20, docetaxel + DC/ TC-1(HHp) 14/19, DC/TC-1-HHp 6/10], the only significant difference was found between the control group and the group of combined chemoimmunotherapy (χ 2 ; docetaxel +DC/TC-1(HHP) vs. Control P<0.01). These results indicate the beneficial effect of the combination of chemotherapy with immunotherapy. The same therapeutic setting was also used for the treatment of poorly immunogenic TRAMP-C2 tumors. As shown in Fig. 7C , monotherapies with docetaxel alone or DC/TraMp-C2(HHp) vaccine alone significantly inhibited growth of TRAMP-C2 tumors. However, when these monotherapies were combined, the therapeutic effect was even stronger. Significant inhibition of tumor growth was found between docetaxel alone or DC/TRAMP-C2(HHP) alone groups and the group treated with a combination of docetaxel and DC/TRAMP-C2(HHP) vaccine (P<0.05). The tumorinhibitory effect was noted as reduction of the size of growing tumors; there was no difference between the incidences of tumors when two independent experiments were merged 
Discussion
HHP has been previously shown to induce endoplasmic reticulum stress and consequently ICD in both murine and human cell lineages (11, 13, 34) . This suggests that HHP, along with other modalities, such as irradiation, photodynamic therapy using hypericin, hyperthermia or treatments with selected chemotherapeutic and cytotoxic agents, can be used for preparation of tumor cells capable of inducing effective antitumor immunity (35) . HHP could also be used for tumor cell inactivation before their use as cellular vaccines or as antigen donors in DC-based vaccines.
In the first part of the study, our aim was to demonstrate the capability of HHP-treated tumor cells to induce immune responses in mice, in comparison with irradiated tumor cells. Lethal irradiation represents a standard procedure used for tumor cell inactivation before their usage for immunization or for DC pulsing, and HHP treatment can serve as an attractive alternative for this procedure. Before performing the in vivo experiments, we optimized the HHP treatments of costimulatory molecule CD274 (B7-H1). This ratio can be considered as an important marker suggesting the DC capability to transmit positive signaling to T cells (39) . Selected cytokine expression levels, including that of IL-12, were lower in DC pulsed with IR-treated tumor cells, as compared to the unpulsed controls. Notably, this was not observed when the HHP-treated tumor cells DC were compared to the unpulsed controls. These results suggest that immature DC co-culture with HHP-treated cells represents a convenient protocol for the DC-based vaccine preparation and corroborates previous findings of Fucikova et al (13) .
The next step was therefore to perform in vivo experiments and to evaluate the immunogenicity of the matured DC pulsed with the HHP-treated tumor cells. As expected, DC vaccines induced much higher IFNγ production by spleen cells as compared to immunization with tumor cells. This, together with further parameters investigated in the spleens (chromium release assay, effector memory CD4 and CD8 cell proportion), suggested that DC vaccines induced strong immunity against TC-1 or TRAMP-C2 tumors, respectively. However, as determined in the immunization-challenge experiments, DC vaccination in a prophylactic setting induced protection against TC-1, but not TRAMP-C2 tumor growth. This was in agreement with IR-and HHP-treated tumor cell immunization, confirming different immunogenicity or sensitivity of the TC-1 and TRAMP-C2 tumors to the immune response induced by prophylactic immunization.
next, we tested the vaccine efficacy in a therapeutic setting in combination with docetaxel chemotherapy, which is clinically relevant especially for prostate cancer treatment (19, 20) . DC-based vaccines are in general intended to be used rather for tumor immunotherapy in a multimodal setting than for immunization. In our experiments, unlike in prophylactic use, the DC treatments of both immunogenic TC-1 and poorly immunogenic/treatable TRAMP-C2 tumors resulted in significant inhibition of the tumor growth, albeit the effect on the TRAMP-C2 appeared to be weaker as compared to the TC-1 tumors. The difference was observed for the therapeutic protocol using docetaxel and DC combination. This treatment led to the highest therapeutic effect, as compared to the chemotherapy or immunotherapy only treatments, in the case of the TRAMP-C2 prostate cancer model. In this model, both chemo-and immunotherapy, when used as monotherapies, displayed only moderate antitumor effects, and additive/ synergistic effects were observed when these treatments were used in combination. On the contrary, synergistic effects of the combination therapy were not seen for the TC-1 therapy. we can speculate that TC-1 tumors are much more vulnerable to immunotherapy, as compared to the TRAMP-C2 tumors, and that it may be difficult to boost it. Moreover, DTX treatment can increase the TRAMP-C2 tumor cell sensitivity to the immune responses.
In conclusion, in the present study we demonstrated that HHP-treatment induced ICD in the cells of TRAMP-C2 and TC-1 murine tumor cell lines. Furthermore, our results show that DC-based vaccines pulsed with HHP-treated cells is an effective instrument for immunotherapy, mainly when combined with chemotherapy, as has been demonstrated in the prostate cancer TRAMP-C2 model, which is poorly immunogenic and difficult to treat.
